CurrentCignaPolicy N/A

Chelating Agents - Trientine Products Prior Authorization Policy

Prior authorization policy for prescription coverage of trientine products (Cuvrior and Syprine/generic) for treatment of Wilson's disease for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyChelating Agents - Trientine Products Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateDec 10, 2025

Key ActionObtain prior authorization and document diagnostic criteria and justification (penicillamine trial or reason for not using penicillamine).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2trientine products listed

1initial approval (years)

3specialist requirement

3non-covered indications

Coverage Criteria for Trientine Products

Approve for 1 year if the patient meets ALL of the following (A, B, and C):

Policy Summary

PayerCigna

PolicyChelating Agents - Trientine Products Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateDec 10, 2025

Key ActionObtain prior authorization and document diagnostic criteria and justification (penicillamine trial or reason for not using penicillamine).

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Overall

A) Diagnostic confirmation
- A.i: Genetic testing confirming biallelic pathogenic ATP7B mutations
  applies to symptomatic or asymptomatic individuals
- A.ii: Confirmation of at least TWO of the following: a) Presence of Kayser-Fleischer rings; b) Serum ceruloplasmin < 20 mg/dL; c) Liver biopsy findings consistent with Wilson's disease; d) 24-hour urinary copper > 40 mcg/24 hours
B) Clinical justification for trientine
- B.i: Prescriber documents patient tried one penicillamine product and is intolerant to penicillamine therapy
- B.ii: Prescriber documents clinical features indicating potential intolerance to penicillamine (examples: history of renal disease; congestive splenomegaly causing severe thrombocytopenia; autoimmune tendency)
- B.iii: Prescriber documents a contraindication to penicillamine therapy
- B.iv: Patient has neurologic manifestations of Wilson's disease
- B.v: Patient is pregnant
- B.vi: Patient has already been started on trientine therapy (Cuvrior or Syprine, generic)
C) Prescriber requirement: Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician
Specialist prescribing or consultation required

ref_id_or_ref???:

ref_strange_field_must_match_block_ref???:

ref_id_must_equal_block_ref???:

ref_must_echo_block_ref_exactly_as_given_in_the_LIST???:

title": "FDA-Approved Indication — Wilson's Disease (Initial approval)"

Trientine products are not indicated and are considered not medically necessary for the conditions listed below. These exclusions are specific to use of Cuvrior (trientine tetrahydrochloride tablets) and Syprine (trientine hydrochloride capsules, including generics) when used for indications other than Wilson's disease.

The policy explicitly lists the following non-covered indications: biliary cirrhosis (trientine is not indicated for treatment of biliary cirrhosis), cystinuria (trientine is not recommended for cystinuria because it lacks a sulfhydryl moiety and cannot bind cysteine), and rheumatoid arthritis (trientine was not found effective in improving clinical or biochemical parameters after 12 weeks in rheumatoid arthritis).

Coding and Clinical Thresholds

Covered productsNDC|HCPCS|mixedCovered

No codes listed

inv-05: 24-hour urinary copper — clinical threshold value

24-hour urinary copper threshold> 40 mcg/24 hours

Role in diagnosisListed as one of the required criteria when confirming Wilson's disease (part of 'two of' criteria).

Source guidanceReferenced in AASLD diagnostic criteria and FDA-approved indication for approval

inv-06: Serum ceruloplasmin — clinical threshold value

Serum ceruloplasmin threshold< 20 mg/dL

Role in diagnosisOne of the clinical features used to confirm Wilson's disease (requires two features if not using genetic testing).

Guideline referenceIncluded in AASLD diagnostic criteria referenced by the policy

Provider Requirements and Authorization Rules

Prior Authorization

Prior Authorization Required

Prior authorization is required for Cuvrior and Syprine (generic). Approvals are provided for the durations specified in the policy and require that the prescriber is a specialist in the condition (gastroenterologist, hepatologist, or liver transplant physician) or that the specialist is consulted.

Cuvrior (trientine tetrahydrochloride tablets)
Syprine (trientine hydrochloride capsules, generic)
Approval duration: 1 year for FDA‑approved indication (Wilson's disease) when criteria met

Documentation Required

Required Clinical Documentation

Documentation must support the diagnosis of Wilson's disease using accepted diagnostic criteria. Diagnosis must be confirmed by either genetic testing showing biallelic pathogenic ATP7B mutations OR by confirmation of at least two clinical features of Wilson's disease. Examples of acceptable clinical documentation include results/reports for Kayser-Fleischer rings, serum ceruloplasmin, liver biopsy, and 24-hour urinary copper.

Genetic testing showing biallelic pathogenic ATP7B mutations; OR
At least TWO of: Kayser-Fleischer rings; serum ceruloplasmin < 20 mg/dL; liver biopsy consistent with Wilson's disease; 24-hour urinary copper > 40 mcg/24 hours
Prescriber specialty: documentation that medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant physician

Documentation Required

Penicillamine Trial or Justification

Policy requires documentation of a trial of penicillamine or a prescriber's justification for not using penicillamine. Acceptable justifications include intolerance, contraindication, clinical features indicating potential intolerance (for example renal disease, severe thrombocytopenia from splenomegaly, autoimmune tendency), neurologic manifestations of Wilson's disease, pregnancy, or that the patient has already been started on trientine therapy.

Documented trial of one penicillamine product (e.g., Cuprimine, Depen) and intolerance to penicillamine; OR
Prescriber statement of contraindication to penicillamine; OR
Prescriber documentation of clinical features indicating potential intolerance to penicillamine (e.g., renal disease, severe thrombocytopenia, autoimmune tendency); OR
Patient has neurologic manifestations of Wilson's disease; OR
Patient is pregnant; OR
Patient has already been started on trientine (Cuvrior or Syprine) — document start date and rationale

Denial Risk

Denial Triggers

Claims lacking a covered diagnosis or required supporting documentation, or use of trientine for excluded indications, will be denied. Ensure submitted claims include covered diagnosis codes and the documentation elements listed above to avoid denial.

Denial risk if no documentation of Wilson's disease per policy criteria
Denial risk if no documentation of penicillamine trial or acceptable justification
Denial risk if trientine is used for excluded indications (e.g., biliary cirrhosis, cystinuria, rheumatoid arthritis)

Background

Trientine products are copper‑chelating agents that promote urinary copper excretion and are used in the management of Wilson's disease (hepatolenticular degeneration). They are available as Syprine (trientine hydrochloride capsules, including generics) and Cuvrior (trientine tetrahydrochloride tablets).

Per the product labeling and policy overview, Syprine is indicated for treatment of patients with Wilson's disease who are intolerant of penicillamine, while Cuvrior is indicated for treatment of adults with stable, de‑coppered Wilson's disease who are tolerant to penicillamine. The policy also notes that trientine is not indicated for cystinuria, rheumatoid arthritis, or biliary cirrhosis and that formulations are not interchangeable on a mg‑for‑mg basis.

Definitions

inv-12: Wilson's disease — definition and diagnostic summary

DefinitionAn autosomal recessive disorder of copper metabolism causing pathologic copper accumulation in liver, brain, kidneys, and cornea.

Diagnostic confirmation — geneticGenetic testing confirming biallelic pathogenic ATP7B mutations confirms the diagnosis.

Diagnostic confirmation — clinical/biochemicalDiagnosis may be confirmed by at least two of: Kayser-Fleischer rings; serum ceruloplasmin <20 mg/dL; liver biopsy consistent with Wilson's disease; 24-hour urinary copper >40 mcg/24 hrs.

Clinical implicationsLifelong pharmacologic therapy is standard; without treatment patients risk progressive liver or neurologic disease and death.